Biological assay challenges from compound solubility: strategies for bioassay optimization

被引：136

作者：

Di, L ^{[1
]}

Kerns, EH ^{[1
]}

机构：

[1] Wyeth Res, Princeton, NJ 08543 USA

来源：

DRUG DISCOVERY TODAY | 2006年 / 11卷 / 9-10期

关键词：

D O I：

10.1016/j.drudis.2006.03.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Compound solubility in buffers and dimethyl sulfoxide (DMSO) has emerged as an important issue. Many discovery compounds have low solubility but are potentially valuable as leads. Unfortunately, low solubility affects bioassays by causing underestimated activity, reduced HTS-hit rates, variable data, inaccurate SAR, discrepancies between enzyme and cell assays and inaccurate in vitro ADME-Tox testing. Strategies for optimizing bioassays include: considering solubility in HTS-library design; early screening for solubility; improving storage and handling of DMSO stocks; optimizing dilution protocols; and ensuring that low-solubility compounds are fully solubilized in bioassays. These approaches allow for adequate assessments of valuable pharmacophores for which solubility can be chemically optimized at a later date.

引用

页码：446 / 451

页数：6

共 49 条

[1]

Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100

[2]

Balakin K. V., 2003, CURR DRUG DISCOV, V8, P27

[3] In silico estimation of DMSO solubility of organic compounds for bioscreening [J].